The court denied defendant's motion to enforce its settlement agreement with plaintiff after the at-risk launch and subsequent settlement of another
The court granted plaintiffs’ motion to dismiss Defendant’s antitrust and patent misuse counterclaims and related affirmative defenses.
“Wherein” clauses in a method of treatment claim are claim limitations that should be given weight, resulting in the affirmance of a preliminary
The asserted claims of 1 ivermectin formulation are invalid on the basis of anticipation in light of a prior art reference that teaches application
But for a clerical error to be addressed on remand, the Federal Circuit affirms findings of ineligible subject matter and non-infringement.
The Federal Circuit affirmed the district court's finding that one of the patents was adequately described, but reversed the district court's finding
Plaintiff's disclaimer of claims found invalid by the PTAB mooted any controversy before the appellate court associated with that patent, and a
Because plaintiffs failed to show specifically how defendants committed any act of infringement in New Jerseyparticularly by filing an ANDA in West
The court denies Defendant’s motion for judgment of non-infringement in response to ANDA holder modification of its ANDA specification after trial.
Plaintiffs own the ’276 patent, which claims the oral methylnaltrexone bromide tablet formulation sold as the constipation drug Relistor. Actavis